Shamburg News · 8-K filed Nov 5, 2026, 4:06 PM EST

Arcturus Therapeutics Reports Q3 2026 Net Loss of $7.4 Million on Revenue of $18.3 Million

ARCT · Arcturus Therapeutics Holdings Inc.

  • Earnings
  • Materiality: high

Arcturus Therapeutics Holdings Inc. reported a net loss of $7.4 million, or $0.26 per share, for the quarter ended September 30, 2026, compared with a net loss of $13.4 million, or $0.49 per share, a year earlier. Total revenue was $18.3 million, including the $12.0 million termination payment and remaining deferred revenue recognized upon termination of the CSL Seqirus collaboration. Cash and cash equivalents were $184.8 million as of September 30, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193805-26-001439.

Written from the filing by Shamburg Markets. Figures are as reported by the company.